571results about How to "Reduce weight loss" patented technology

The invention discloses a low-density, high-rigidity and high-tenacity polypropylene nano composite material and a preparation method thereof. The low-density, high-rigidity and high-tenacity polypropylene nano composite material consists of the following raw materials in percentage by weight: 55 to 98 percent of polypropylene, 1 to 15 percent of organic clay, 0 to 30 percent of inorganic filler, 0.1 to 10 percent of compatilizer, 0 to 20 percent of toughening agent, 0.2 to 2 percent of stabilizing agent, and 0 to 5 percent of other additives. The low-density, high-rigidity and high-tenacity polypropylene nano composite material and the preparation method have the following advantages that: 1, the density and the weight of a product are reduced for the help of reducing the weight and the energy consumption of a finished product; 2, the rigidity and the tenacity are higher; 3, the process flow is simplified and the production cost is reduced effectively; and 4, the influences on the cutting of nano clay and the dispersion process caused by other components are avoided to the utmost extent to further improve the performance of the composite material.

The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.

Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.

The invention relates to a high-boron iron-based wear-resistant surfacing flux-cored welding wire. The welding wire is composed of a low-carbon steel sheath and core powder, and is characterized in that the iron element in the low-carbon steel sheath and the core powder, and the iron element in the core powder Elements include boron, carbon, manganese, and silicon. The weight percentage of boron, carbon, manganese, and silicon in the core powder is: boron 6-12%, carbon 0.1-3%, manganese 0.6-2%, silicon 0.3-1.5%, the balance is iron. It may also include 0.3-3.5% of Ti, 0.6-2% of Mn, 0.3-1.5% of Si, 0-1% of molybdenum, 0-1% of K / Na modifier, and 0-1.5% of aluminum-magnesium alloy. The high-boron iron-based wear-resistant surfacing flux-cored welding wire of the present invention mainly relies on boron, titanium, carbon and other alloy elements to form borides and a small amount of carbides to realize the wear resistance of the surfacing alloy, and by adding rare earth, nickel, Aluminum-magnesium alloys, etc. improve the comprehensive performance of surfacing alloys.

Methods and pharmaceutical compositions for preconditioning and / or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and / or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and / or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and / or post stroke.

The invention provides a catalyst for use in synthesis of dioctyl terephthalate and a method for preparing dioctyl terephthalate by applying the catalyst. The catalyst consists of a catalyst 1 and a catalyst 2, wherein the catalyst 1 consists of an ionic liquid and a metal compound; the catalyst 2 consists of a titanium metal compound and other metal compound; the positive ion of the ionic liquid are an imidazole ion or a benzimidazole ion; the negative ion of the ionic liquid is a bisulfate ion; or the positive ion of the ionic liquid is a benzimidazole ion or an imidazole ion with one or two sulfonic acid radicals; the titanium metal compound is selected from at least one compound of tetrabutyl titanate, isopentyl ester titanate, isopropyl titanate or titanium dioxide; and the other compound is selected from at least one compound of dibutyldimethoxytin, dibutyltin oxide, monooctyl ester stannite, zinc acetate and cobalt acetate. Due to the adoption of the technical scheme provided by the invention, the cost can be reduced, the reaction speed is increased, energy consumption is lowered, and the quality of an obtained product is high.

The invention provides for a method of treating inappetance-induced weight loss in one or more companion animals or livestock. The method provides for administering a therapeutically effective amount of a capromorelin-containing composition to the companion animal or livestock. Optionally, one or more flavoring agents or flavor-masking agents can be added to the capromorelin-containing composition to enhance or mask the flavoring of the composition for the companion animal or livestock.